Prof. Dr. Richard P. Baum, Nuclear Medicine Physician at Curanosticum Wiesbaden in Germany, President of the ICPO Academy for Theranostics, and Chairman of the Scientific Advisory Board of the ICPO Foundation, is a pioneer and globally renowned expert in Radiomolecular Precision Oncology including treatment of neuroendocrine tumors and prostate cancer. His groundbreaking research and clinical experience have been instrumental in developing new treatment approaches for cancer patients. With nearly 40 years of invaluable experience, Prof. Baum's expertise and insights enrich the Board, driving forward the mission of the ICPO Foundation with unparalleled depth and understanding. Over the past years, he and his team have treated over 2000 NET (Neuroendocrine Tumor) patients worldwide with more than 7000 Peptide Receptor Radionuclide Therapy (PRRT) applications. He was honored with many prizes, such as the Mallinckrodt Award in 1990, the GLORINET Award in 2014 (NET Patients Support Group in Germany), and the Saul Hertz Award in 2019 by the SNMMI (one of the most prestigious lifetime awards in the field of nuclear medicine therapy). Richard P. Baum holds several guest and associate professorships across the continents, such as at Michigan State University in the U.S. and at the Peking University Cancer Hospital in China.
